Advertisement
Canada markets close in 4 hours 13 minutes
  • S&P/TSX

    22,183.99
    +76.91 (+0.35%)
     
  • S&P 500

    5,252.31
    +3.82 (+0.07%)
     
  • DOW

    39,767.19
    +7.11 (+0.02%)
     
  • CAD/USD

    0.7388
    +0.0015 (+0.21%)
     
  • CRUDE OIL

    82.47
    +1.12 (+1.38%)
     
  • Bitcoin CAD

    96,408.20
    +2,865.91 (+3.06%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,234.80
    +22.10 (+1.00%)
     
  • RUSSELL 2000

    2,130.93
    +16.58 (+0.78%)
     
  • 10-Yr Bond

    4.1910
    -0.0050 (-0.12%)
     
  • NASDAQ

    16,393.66
    -5.87 (-0.04%)
     
  • VOLATILITY

    12.95
    +0.17 (+1.33%)
     
  • FTSE

    7,967.30
    +35.32 (+0.45%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6836
    +0.0031 (+0.46%)
     

Collegium Pharmaceutical (COLL) Reports Q1 Earnings: What Key Metrics Have to Say

Collegium Pharmaceutical (COLL) reported $144.77 million in revenue for the quarter ended March 2023, representing a year-over-year increase of 72.9%. EPS of $1.32 for the same period compares to $0.60 a year ago.

The reported revenue represents a surprise of +4.07% over the Zacks Consensus Estimate of $139.11 million. With the consensus EPS estimate being $1.32, the company has not delivered EPS surprise.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Collegium Pharmaceutical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Total product revenues- Belbuca: $44.21 million versus the four-analyst average estimate of $41.48 million.

  • Total product revenues- Nucynta: $49.04 million versus $46.38 million estimated by four analysts on average.

  • Total product revenues- Symproic: $3.65 million versus $4.03 million estimated by four analysts on average.

  • Total product revenues- Xtampza ER: $47.87 million compared to the $47.02 million average estimate based on four analysts.

View all Key Company Metrics for Collegium Pharmaceutical here>>>

Shares of Collegium Pharmaceutical have returned -5.9% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Collegium Pharmaceutical, Inc. (COLL) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research